October 14, 2009 (Baltimore, Maryland) — A new study using data from the National Inpatient Sample, a nationally representative database, shows that although thrombolytic therapy with recombinant ...

HONOLULU, HI—Patients with acute ischemic stroke who have salvageable brain tissue identified with advanced imaging appear to benefit from IV tissue plasminogen activator (tPA) beyond ...

Making the switch from alteplase to tenecteplase for stroke thrombolysis can be done successfully when the appropriate preparations are taken, and it may improve patient outcomes, the experience of a ...

June 3, 2011 — The rate of thrombolytic therapy use in the United States approximately doubled from 2005 to 2009, a new study shows. By conservative estimates, 3.4% to 5.2% of ischemic stroke patients ...

Comprehensive protocols in emergency departments (EDs) can allow rapid assessment of stroke patients eligible for early-stage treatment, according to a study published in the latest Medical Journal of ...

Intravenous thrombolysis with recombinant tissue plasminogen activator (IV rtPA) is an established and effective treatment for acute ischaemic stroke. 1,2,3 tPA is a serine protease that catalyses the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Thrombolytic Science, LLC (TSI) today announced initiation of a Phase 2 clinical trial to confirm the efficacy and safety of its sequential dual-treatment regimen of ...

Background: Thrombolysis for acute ischemic stroke has remained controversial. The Canadian Alteplase for Stroke Effectiveness Study, a national prospective cohort study, was conducted to assess the ...

Patients admitted to stroke centers for acute ischemic stroke had lower 30-day all-cause mortality and more frequently used thrombolytic therapy when compared with nondesignated hospitals, new data ...

Neurologists around the world are aware that the delivery of thrombolytic treatment for stroke in Helsinki University Hospital, Finland, is freaking fast - but is it too fast? A new study published on ...